Fluidic Analytics Fluidity One-W for antibody affinity and concentration in undiluted serum

Thursday, 01 April, 2021 | Supplied by: ATA Scientific Pty Ltd



The emergence of mutant variants of SARS-CoV-2 and associated concerns about the effects of these mutations on the efficacy of vaccines and therapeutics has underscored the vital importance of understanding the antibody response to SARS-CoV-2.

Using the Fluidity One-W, measurements to determine the affinity, concentration and neutralisation potential of antibodies can be performed directly in human serum. In the recent paper ‘In vitro measurements of protein–protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum’ the capabilities of the Fluidity One-W serum platform were shown.

The product offers an in-solution, receptor-binding competition assay that quantifies the affinity, concentration and neutralisation potential of antibodies against the SARS-CoV-2 spike protein. The platform has the ability to quantitatively profile the underlying protein interactions directly in serum.

Scientists who would like to book a trial, to see how the capabilities of the Fluidity One-W serum can support their research, can do so by contacting ATA Scientific.

For more information: https://www.fluidic.com/resources/antibody-affinity-governs-inhibition-of-SARS-CoV-2/.

Online: www.atascientific.com.au
Phone: 02 9541 3500
Related Products

PBL VeriKine-HS Human IFN Beta TCM ELISA Kit

The VeriKine-HS Human Interferon Beta TCM ELISA Kit features sensitive detection and...

Cayman Chemical ACE2 Inhibitor Screening Assay Kit

Cayman Chemical's ACE2 Inhibitor Screening Assay Kit provides a robust and easy-to-use...

Merck CRISPRi whole-genome libraries and pools

Merck has launched its CRISPR inhibition (CRISPRi) whole-genome libraries and pools to complement...


  • All content Copyright © 2021 Westwick-Farrow Pty Ltd